European Neuropsychopharmacology

Neuroendocrine studies in depression
pp. S4/1-S4/1(1)
Author: Holsboer F.

Personality disorders are disorders of the personality
pp. S4/1-S4/2(1)
Author: Lopez-Ibor J.J.

Receptors for ATP: New structures and new therapeutic targets
pp. S4/2-S4/2(1)
Author: Barnard E.A.

Does severe depression have a different pharmacology?
pp. S4/3-S4/4(1)
Authors: Aschauer H.N.; Kasper S.

Adjunctive therapy in severe depression
pp. S4/4-S4/4(1)
Author: Dinan T.G.

Modulation of drug reward by receptor ligands
pp. S4/4-S4/5(1)
Authors: Zvartau E.; Bespalov A.; Kuzmin A.; Patkina N.; Semenova S.

Involvement of corticotropin-releasing factor in addiction
pp. S4/5-S4/5(1)
Authors: Heinrichs S.C.; Rassnick S.; Schulteis G.; Menzaghi F.; Pich E.M.; Richter R.; Weiss F.; Koob G.F.

Endorphins and experimental drug addiction
pp. S4/5-S4/6(1)
Authors: Gerrits M.A.F.M.; van Ree J.M.

Opiate antagonists in the treatment of alcohol dependence: Results of a UK study
pp. S4/6-S4/7(1)
Author: Chick J.D.

Acamprosate and relapse prevention: Results from a pooled analysis of 11 randomised placebo-controlled trials in 3338 alcohol-dependent patients
pp. S4/7-S4/7(1)
Authors: Sass H.; Potgieter A.S.; Lehert P.

Functional Magnetic Resonance Imaging as a research tool: Quality assessment of PRESTO, a non-invasive three-dimensional imaging technique
pp. S4/7-S4/8(1)
Authors: Ramsey N.F.; van Gelderen P.; Tallent K.; Callicott J.H.; Moonen C.T.W.; Weinberger D.R.

PET studies on the dopamine system in vivo
pp. S4/8-S4/8(1)
Authors: Farde L.; Ginovart N.; Halldin C.

Studies of cerebral blood flow with SPET and PET - Promises and pitfalls
pp. S4/8-S4/9(1)
Author: McGuire P.K.

Magnetoencephalography (MEG) in the study of human brain functions
pp. S4/9-S4/9(1)
Author: Sams M.

Event related potentials as indicators of central serotonergic activity
pp. S4/9-S4/10(1)
Authors: Hegerl U.; Juckel G.; Moller H.-J.

Metabotropic receptors and their involvement in cell death
pp. S4/10-S4/10(1)
Authors: Pizzi M.; Galli P.; Consolandi O.; Boroni F.; Gavazova S.; Benarese M.; Memo M.; Spano P.F.

Novel neuroprotective strategies based on the enhancement of brain kynurenic acid levels
pp. S4/10-S4/11(1)
Author: Schwarcz R.

MAO and COMT: basic functions and therapeutic indications
pp. S4/11-S4/12(1)
Authors: Richards J.G.; Saura J.; Bleuel Z.; Malherbe P.; Cesura A.M.; Borroni E.; Gottowik J.; Gray J.

The treatment of the schizophrenic patient: How far have we come in meeting the challenge
pp. S4/12-S4/13(1)
Author: Kane J.M.

Negative symptoms and sertindole
pp. S4/13-S4/13(1)
Author: Kasper S.

Negative symptoms and risperidone
pp. S4/13-S4/14(1)
Author: Peuskens J.

The course of primary and secondary negative symptoms in a placebo- and comparator-controlled trial of the typical antipsychotic olanzapine
pp. S4/14-S4/14(1)
Authors: Tollefson G.D.; Sanger T.M.; Beasley C.M.

A review of the efficacy of ''Seroquel'' (quetiapine) in the treatment of the positive and negative symptoms of schizophrenia ]
pp. S4/14-S4/15(1)
Authors: Hellewell J.S.E.; Hurst B.C.

Natural course of OCD
pp. S4/15-S4/15(1)
Authors: Ravizza L.; Barzega G.; Bellino S.; Bogetto F.; Maina G.

The place of cognitive therapy in the treatment of obsessive compulsive disorder
pp. S4/16-S4/16(1)
Authors: van Oppen P.; van Balkom A.J.L.M.; de Haan E.; Spinhoven P.; Hoogduin C.A.L.; van Dyck R.

PANDAS: Pediatric Autoimmune Neuropsychiatric Disorders Associated with Strep - Is this a new species of childhood-onset obsessive-compulsive disorder and Tourette's syndrome?
pp. S4/16-S4/17(1)
Authors: Swedo S.E.; Leonard H.L.; Garvey M.A.; Mittleman B.B.

Genetics and function of GABA_A-receptor subtypes
pp. S4/17-S4/17(1)
Authors: Mohler H.; Fritschy J.-M.; Benke D.; Benson J.; Luscher B.

Neuroactive steroids acting at GABA_A receptors
pp. S4/17-S4/18(1)
Author: Gee K.W.

PET Imaging of benzodiazepine receptors and their relationship to anxiety disorders
pp. S4/19-S4/19(1)
Authors: Nutt D.J.; Malizia A.L.; Wilson S.J.

The dopamine receptors and schizophrenia therapy
pp. S4/19-S4/20(1)
Authors: Civelli O.; Hartman D.

Serotonin-related strategies for the treatment of schizophrenia
pp. S4/20-S4/21(1)
Authors: Meltzer H.Y.; Ichikawa J.; Kuroki T.; Roth B.

Adenosine A_2A agonists: A potential, new type of atypical antipsychotics
pp. S4/21-S4/22(1)
Authors: Ogren S.O.; Ferre S.; Rimondini R.; Fuxe K.

Selective versus non-selective neuroleptics: Advantages and disadvantages
pp. S4/22-S4/22(1)
Authors: Ackenheil M.; Macher J.-P.

Rapid onset of antidepressant action in an animal model of depression
pp. S4/22-S4/22(1)
Authors: Papp M.; Willner P.

Combination treatments with rapid onset of action in major depression
pp. S4/23-S4/23(1)
Authors: Blier P.; Bergeron R.

BIMT 17: A putative fast acting antidepressant
pp. S4/23-S4/24(1)
Author: Borsini F.

Does Venlafaxin have early onset?
pp. S4/24-S4/24(1)
Author: Moller H.-J.

The amyloid hypothesis in Alzheimer's disease and its implication for therapy: A review of evidence
pp. S4/24-S4/25(1)
Authors: Beyreuther K.; Tienari P.J.; Ikonenen E.; Multhaup G.; Hartman T.; Simons M.; Dotti C.G.; Masters C.L.

Neuropathology of Alzheimer's disease with special reference to neurofibrillary tangles
pp. S4/25-S4/26(1)
Authors: Braak H.; Braak E.; Yilmazer D.; Bohl J.

Role of inflammation, Apo E, and antichymotrypsin in Alzheimer's disease
pp. S4/26-S4/26(1)
Author: Potter H.

Molecular genetic studies in affective disorders
pp. S4/26-S4/27(1)
Author: Mendlewicz J.

Antisense ''knockout'' of brain dopamine receptors: Potential antipsychotics?
pp. S4/27-S4/27(1)
Author: Creese I.

Immediate early genes: Functions and responses to drugs
pp. S4/27-S4/28(1)
Author: Morgan J.I.

Possible cross-tolerance between haloperidol and clozapine towards Fos-protein induction in some rat brain regions
pp. S4/28-S4/29(1)
Authors: Sebens J.B.; Koch T.; Korf J.

Neurotransmitter receptors, genes and schizophrenia
pp. S4/29-S4/30(1)
Author: Reynolds G.P.

Epileptic agents in bipolar depression
pp. S4/30-S4/30(1)
Author: Ferrier I.N.

Lithium withdrawal: Clinical consequences and changes in brain perfusion
pp. S4/30-S4/31(1)
Author: Goodwin G.M.

Treatment options in refractory bipolar disorder, methodological problems and clinical opportunities
pp. S4/31-S4/31(1)
Authors: Nolen W.A.; Rumke groep H.C.; Huis W.A.

Course of illness in schizophrenia in relation to duration of initially untreated psychosis
pp. S4/31-S4/32(1)
Authors: Waddington J.L.; Scully P.J.; Coakley G.; Kinsella A.

Relapse prevention with neuroleptics in schizophrenia: The role of their bioavailability and pharmacodynamic profile
pp. S4/32-S4/33(1)
Author: Altamura A.C.

Early intervention and the course of illness
pp. S4/33-S4/33(1)
Authors: Schooler N.R.; Keshavan M.S.; Haas G.L.; Sweeney J.A.

Inflammation and anti-inflammatory treatment strategies in Alzheimer's disease
pp. S4/34-S4/34(1)
Authors: Winblad B.; Schultzberg M.

Stress and depression: A hypothesis on their biological interface
pp. S4/34-S4/35(1)
Author: van Praag H.M.

Social defeat in rats as model for depression
pp. S4/35-S4/35(1)
Authors: Koolhaas J.M.; Meerlo P.; de Boer S.F.; Strubbe J.H.

Disruption of circadian rhythms in possible animal models for depression
pp. S4/35-S4/36(1)
Authors: Turek F.W.; Zee P.; Buxton O.; Van Reeth O.; Penev P.

The behavioral and neural biology of ''social stress''
pp. S4/36-S4/37(1)
Authors: Miczek K.A.; Tornatzky W.; van Erp A.M.M.

Social phobia: Treatment usage in general health care
pp. S4/37-S4/37(1)
Authors: Weiller E.; Bisserbe J.C.; Lepine J.P.; Boyer P.; Lecrubier Y.

Cognitive and behaviourial therapies for social phobia
pp. S4/37-S4/38(1)
Author: Freeman C.P.L.

Treatment of social phobia with SSRIs
pp. S4/38-S4/39(1)
Authors: Greist J.H.; Katzelnick D.J.; Jefferson J.W.; Kobak K.A.

RIMAs in social phobia
pp. S4/39-S4/39(1)
Author: Buller R.

The need for treatment of social phobia
pp. S4/39-S4/39(1)
Author: Costa e Silva J.A.

5-HT_1A receptors, anxiety and stress: Behavioural, neuroendocrine and physiological interfaces
pp. S4/39-S4/40(1)
Authors: Olivier B.; Groenink L.; Hijzen T.; van der Gugten J.

Neurotherapeutic potential of 5-HT₃ receptor antagonists
pp. S4/41-S4/42(1)
Authors: Palfreyman M.G.; Sorenson S.M.; Gittos M.W.; Moser P.C.; Kehne J.H.; Dudley M.W.; Fozard J.R.

5-HT₆ and 5-HT₇ receptors: New targets for neuropsychiatry
pp. S4/42-S4/43(1)
Authors: Sleight A.J.; Boess F.G.; Monsma F.J.; Bourson A.

Dopamine-GABA interactions in relation to schizophrenia
pp. S4/43-S4/44(1)
Author: Benes F.M.

Developmental processes and immunology in schizophrenia
pp. S4/44-S4/44(1)
Authors: Muller N.; Schwarz M.; Riedel M.; Ackenheil M.

The effects of neuroleptics in rats with neonatal hippocampal damage; A search for more effective treatment of schizophrenia
pp. S4/44-S4/45(1)
Authors: Lipska B.K.; Lillrank S.M.; Weinberger D.R.

A meta-analysis of magnetic resonance imaging studies in schizophrenia
pp. S4/45-S4/45(1)
Authors: Vita A.; Dieci M.; Tenconi F.

A double action antidepressant: Venlafaxine
pp. S4/45-S4/46(1)
Author: Puech A.J.

Mirtazapine: A dual action antidepressant which does not affect monoamine reuptake
pp. S4/46-S4/46(1)
Author: Pinder R.M.

Milnacipran, a double noradrenaline and serotonin reuptake inhibiting antidepressant
pp. S4/46-S4/46(1)
Author: Briley M.

Animal models of panic disorder -- Emphasis on face and predictive validity
pp. S4/47-S4/47(1)
Authors: Jenck F.; Martin J.R.; Moreau J.-L.

Panic disorder: Do we know the best way to treat it?
pp. S4/47-S4/48(1)
Author: Anderson I.M.

The future of CCK agonists and antagonists in panic disorder and anxiety
pp. S4/48-S4/48(1)
Authors: Bourin M.; Vasar E.

Time course of inositol treatment of panic disorder
pp. S4/48-S4/49(1)
Authors: Benjamin J.; Fux M.; Belmaker R.H.

Pharmacological discrimination of native and recombinant rat and human N-methyl-D-aspartate receptors
pp. S4/49-S4/50(1)
Author: Priestley T.

Molecular pharmacology of NMDA receptors
pp. S4/50-S4/50(1)
Author: Williams K.

The pharmacology of native NMDA receptor subtypes
pp. S4/50-S4/51(1)
Authors: Carter C.; Fage D.; Klarica M.; Nankai M.

The development of brain and behavior
pp. S4/51-S4/51(1)
Author: Insel T.R.

Neonatal pain and stress: Neural adaptations and long-term consequences
pp. S4/51-S4/52(1)
Authors: Plotsky P.M.; Eisler J.A.; Anand K.J.S.

Effects of differential early social experience on biological and behavioral development in rhesus monkeys
pp. S4/52-S4/52(1)
Author: Suomi S.J.

Studies in nonhuman primates provide insights into the dysregulation of emotional responses and psychopathology
pp. S4/52-S4/52(1)
Author: Kalin N.H.

Evaluating the benefits of antidepressant therapy - Modelling the impact on quality of life
pp. S4/52-S4/53(1)
Author: Kind P.

Controlled trials versus naturalistic studies
pp. S4/53-S4/54(1)
Author: Brown R.E.

Managed care and antidepressant pharmacotherapy: Economic considerations
pp. S4/54-S4/54(1)
Authors: Robison L.M.; Sclar D.A.; Skaer T.L.

Cost-effectiveness of treatments for schizophrenia
pp. S4/54-S4/54(1)
Authors: Kerwin R.W.; Aitchison K.J.

Is 5HT_1A involved in obsessive compulsive disorder?
pp. S4/54-S4/55(1)
Author: Zohar J.

Neurosurgery for otherwise intractable OCD -- An update
pp. S4/55-S4/56(1)
Authors: Mindus P.; Lippitz B.; Andreewitch S.; Nyman H.; Hindmarsh T.; Lindquist C.; Meyerson B.A.

Genetics of the Gilles de la Tourette syndrome and obsessive compulsive disorder
pp. S4/56-S4/56(1)
Author: Pauls D.L.

Neuroimaging studies in children with Tourette syndrome and obsessive-compulsive disorder
pp. S4/56-S4/57(1)
Authors: Buitelaar J.K.; de Bruin W.I.; van Rijk P.P.; van Engeland H.

Finding susceptibility genes for schizophrenia
pp. S4/57-S4/58(1)
Author: Owen M.J.

New molecular genetic studies in affective disorders
pp. S4/58-S4/58(1)
Author: Propping P.

Anticipation and dynamic mutations in psychiatry
pp. S4/58-S4/59(1)
Authors: Souery D.; Lipp O.; Mahieu B.; Van Broeckhoven C.; Mendlewicz J.

Gene-environment interactions in complex psychiatric disorders
pp. S4/59-S4/59(1)
Authors: Macciardi F.; Cavallini M.C.; Namia C.; Bossi S.; Cauli G.; Franchini L.; Verga M.; Serretti A.; Morabito A.; Smeraldi E.

Prodromes of schizophrenia
pp. S4/59-S4/60(1)
Authors: Maurer K.; Hafner H.

Fluvoxamine augmentation in citalopram non-responders: A pharmacokinetic and clinical study
pp. S4/61-S4/61(1)
Authors: Bondolfi G.; Chautems C.; Baumann P.

Patterns of mood improvement with mirtazapine
pp. S4/61-S4/61(1)
Authors: Kremer C.M.E.; Zivkov M.; Helsdingen J.T.

Efficacy of mirtazapine vs clomipramine in severely depressed, hospitalized patients
pp. S4/61-S4/61(1)
Author: Peyron E.

Lack of typical SSRI-related adverse effects and sexual dysfunction with mirtazapine is related to specific blockade of 5-HT₂ and 5-HT₃ receptors
pp. S4/61-S4/62(1)
Authors: Klint T.; Helsdingen J.T.; Kremer C.M.E.; Zivkov M.

Mirtazapine versus tricyclic antidepressants: An overview of efficacy data
pp. S4/62-S4/62(1)
Authors: Sitsen J.M.A.; Kremer C.M.E.; Slinning H.; Helsdingen J.T.

Safety of mirtazapine in overdose
pp. S4/62-S4/62(1)
Authors: Zivkov M.; Kremer C.M.E.; Hoes M.J.A.J.M.; Blokland E.; Helsdingen J.T.

Efficacy of mirtazapine in moderate and severe depression
pp. S4/62-S4/62(1)
Authors: Pinder R.M.; Kremer C.M.E.; Zivkov M.; Helsdingen J.T.; Blokland E.

Mirtazapine versus tricyclic antidepressants in the treatment of severely depressed patients
pp. S4/62-S4/63(1)
Authors: Zivkov M.; Muhring A.; Kremer C.M.E.

Characterization and inhibition of human cytochrome P-450 enzymes involved in the in vitro metabolism of mirtazapine
pp. S4/63-S4/63(1)
Authors: Verhoeven C.H.J.; Vos R.M.E.; Bogaards J.J.P.

Pharmacology and the relevance for choice
pp. S4/63-S4/63(1)
Author: Preskorn S.H.

Clinical profile of mirtazapine
pp. S4/63-S4/64(1)
Author: van Moffaert M.

Pharmacokinetics and relevance for choice
pp. S4/64-S4/64(1)
Author: Delbressine L.P.C.

Mental retardation: Effectiveness of fluvoxamine in the treatment of depressive symptoms: Case reports
pp. S4/64-S4/64(1)
Authors: Lenzi A.; Rastelli T.F.; Bianco I.; Gianfranchi C.L.

Risperidone in the treatment of rapid cycling bipolar disorder
pp. S4/64-S4/65(1)
Authors: Vieta E.; Gasto C.; Otero A.; Vallejo J.

The safety profile of fluvoxamine in elderly patients
pp. S4/65-S4/65(1)
Authors: Wagner W.; Hauser V.; L. F.W.

Fluvoxamine effective in preventing recurrence of major depression
pp. S4/65-S4/65(1)
Authors: Terra J.L.; Noel F.

The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects
pp. S4/65-S4/66(1)
Authors: Puechler K.; Schaffler K.; Wauschkuhn C.-H.; Plenker A.

The safety and tolerability profile of a new RIMA antidepressant, RS-8359 in healthy subjects and depressed patients
pp. S4/66-S4/66(1)
Authors: Puechler K.; Plenker A.; Volz H.-P.; Witte P.U.

The effects of a new RIMA antidepressant RS-8359 on cardiovascular function
pp. S4/66-S4/66(1)
Authors: Puechler K.; Plenker A.; Volz H.-P.; Witte P.U.

Serotonergic mechanisms in the pathophysiology of seasonal affective disorder
pp. S4/66-S4/67(1)
Authors: Neumeister A.; Praschak-Rieder N.; Hesselmann B.; Rauh M.; Barocka A.; Vitouch O.; Kasper S.

Low serum cholesterol, serotonin and suicidal behavior
pp. S4/67-S4/67(1)
Authors: Pitchot W.; Hild B.; Ansseau M.

Platelet serotonin, ³H-paroxetine binding and recurrent suicide attempts: A one-year follow up study
pp. S4/67-S4/67(1)
Authors: Verkes R.J.; Fekkes D.; Hengeveld M.W.; Van der Mast R.C.; Tuyl J.P.; Van Kempen G.M.J.

Synergistic increases of noradrenaline and 5-HT neurotransmission induced by milnacipran with pindolol
pp. S4/68-S4/68(1)
Authors: Moret C.; Briley M.

Milnacipran, a double noradrenaline and 5-HT reuptake inhibiting antidepressant increases cerebral extracellular monoamine levels
pp. S4/68-S4/68(1)
Authors: Moret C.; Briley M.

Flesinoxan: microdialytic profiling of a 5-HT_1A receptor agonist
pp. S4/68-S4/69(1)
Authors: van der Heyden J.A.M.; Bosch A.I.; de Rond E.J.; Long S.K.

Prolactin and TSH responses to TRH and to ECT in pre- and post-menopausal women with major depression
pp. S4/69-S4/69(1)
Authors: Lykouras E.; Markianos M.; Stefanis C.

Treatment of sleep disturbance and pain syndrome in fibromyalgia patients with the 5-HT2-receptor antagonist ketanserine
pp. S4/69-S4/69(1)
Authors: Hemmeter U.; Kocher R.; Hatzinger M.; Seifritz E.; Bischof R.; Lauer C.J.; Holsboer-Trachsler E.

The Vienna outpatient-clinic for therapy-resistant depression
pp. S4/69-S4/70(1)
Authors: Lenz G.; Bailer U.; Serim M.; Schumann C.

Antidepressant effects of tianeptine, of its two enantiomers and its predominant metabolite in the learned helplessness test in rats
pp. S4/70-S4/70(1)
Authors: Lacroix P.; Rocher N.; Deslandes A.

The effect of antimanic drugs on the hypermotility response to intracerebroventricular administration of ouabain in the rat
pp. S4/70-S4/71(1)
Authors: Piper D.C.; Cooper D.A.; Upton N.

Localization of 5HT_1D- and 5HT_1D-receptor mRNA by in situ hybridization in guinea pig brain and trigeminal ganglia
pp. S4/71-S4/71(1)
Authors: Bonaventure P.; Voorn P.; Luyten W.H.M.L.; Schotte A.; Leysen J.E.

Selective serotonin reuptake inhibitors: Adverse drug reactions registered by SANZ-Swiss spontaneous reporting system
pp. S4/71-S4/71(1)
Authors: Spisla C.; Bunter M.; Hartmann K.; Kuhn M.

Efficacy and safety of fluoxetine in major depression
pp. S4/71-S4/72(1)
Author: Cetin M.

Antidepressant therapy and dopamine D₂ receptors measured with SPECT
pp. S4/72-S4/72(1)
Authors: D'haenen H.; Steenssens D.; Flamen F.; Everaert H.; Bossuyt A.

Tolerance and therapeutic response of paroxetine in the depressed elderly
pp. S4/72-S4/72(1)
Authors: De la Serna I.; Fernandez Camacho A.

Flesinoxan in the treatment of major depressive disorder: A fixed dose, placebo-controlled trial
pp. S4/73-S4/73(1)
Authors: Prinsze C.; Stevens G.

Clinical and neuroendocrine response to fluvoxamine treatment in impulsive borderline personality disorder
pp. S4/73-S4/73(1)
Authors: Rinne T.; Gans E.; Vernimmen R.; den Boer J.A.; Westenberg H.G.M.; van Tilburg W.

Therapeutic monitoring of amitriptyline, fluvoxamine and lithium in depressed patients on combined therapy
pp. S4/73-S4/74(1)
Authors: Miljkovic B.; Pokrajac M.; Timotijevic I.; Varagic V.

Fluvoxamine versus desipramine in elderly patients with major depression: A double-blind comparison
pp. S4/74-S4/74(1)
Authors: Tourigny-Rivard M.; Nair N.P.V.; Vincent P.

Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist in the forced swimming test in rats
pp. S4/74-S4/74(1)
Authors: Deren-Wesolek A.; Tatarczynska E.; Przegalinski E.; Chojnacka-Wojcik E.

Antibodies against serotonin and gangliosides in fibromyalgia and major depression
pp. S4/74-S4/75(1)
Authors: Samborski W.; Sluzewska A.; Klein R.; Sobieska M.; Lecki J.; Stratz T.; Mueller W.

Clinical relevance of antibodies against serotonin and gangliosides, and acute phase proteins in major depression
pp. S4/75-S4/75(1)
Authors: Sluzewska A.; Samborski W.; Sobieska M.; Klein R.

Toxicity of antidepressant drugs: A comparative in vitro study
pp. S4/75-S4/75(1)
Authors: Lisch S.; Holsboer F.; Behl C.

Effects of selective serotonin reuptake inhibitors given repeatedly on 5-HT receptor subpopulations in the rat brain
pp. S4/75-S4/75(1)
Authors: Maj J.; Dziedzicka-Wasylewska M.; Klimek V.; Moryl E.; Rogoz Z.; Skuza G.

Flesinoxan, a selective 5-HT_1A receptor agonist, familiarizes with fluvoxamine and fluoxetine in a conditioned taste aversion procedure in mice
pp. S4/76-S4/76(1)
Authors: Bouwknecht J.A.; Gommans J.; Hijzen T.H.; Berendsen H.H.G.; Olivier B.

Comparison of amisulpride and selective serotonine reuptake inhibitors efficacy on cognitive and anxious symptoms in dysthymic disorder
pp. S4/76-S4/76(1)
Authors: Scotta M.; Fonzo V.; Rocca P.; Zanalda E.; Ravizza L.

The effect of antidepressants on platelet serotonin level and serotonin uptake in rats genetically selected for these traits
pp. S4/76-S4/77(1)
Authors: Cicin-Sain L.; Frobe A.; Jernej B.

Messenger RNA for platelet 5HT transporter protein: Studies in rats with constitutionally altered serotonin homeostasis
pp. S4/77-S4/77(1)
Authors: Jernej B.; Hranilovic D.; Cicin-Sain L.

Pharmacoethological investigation GABA-ergic regulation of aggression and depression: Animal models
pp. S4/77-S4/78(1)
Author: Belozertseva I.V.

Tryptophan depletion and neurohormonal regulation in remitted patients with seasonal affective disorder
pp. S4/78-S4/78(1)
Authors: Hesselmann B.; Neumeister A.; Praschak-Rieder N.; Kasper S.

Left hemispheric relative hypoperfusion in depressed patients with seasonal affective disorder responding to light therapy
pp. S4/78-S4/78(1)
Authors: Praschak-Rieder N.; Neumeister A.; Hesselmann B.; Bailer U.; Asenbaum N.; Podreka I.; Kasper S.

Combined pharmakotherapy (Tramadon and Mianserin) in chronic pain syndrome
pp. S4/78-S4/79(1)
Author: Marko M.G.

Time-blind assessment of antidepressant efficacy in depressed patients
pp. S4/79-S4/79(1)
Authors: Corruble E.; Purper D.; Payan C.; Puech A.J.; Guelfi J.D.

Reduced 5-HT in CSF: Trait or state marker for suicidality?
pp. S4/79-S4/80(1)
Authors: Becker U.; Laakmann G.; Baghai T.; Kuhn K.; Pfeifer B.; Kauert G.

Blunted reaction to the citalopram challenge test in patients with major depression
pp. S4/80-S4/80(1)
Authors: Kapitany T.; Schindler S.D.; Hesselmann B.; Schindl M.; Barnas C.; Sieghart W.; Kasper S.

Neuroendocrine challenge of serotonergic function with citalopram in healthy volunteers
pp. S4/80-S4/80(1)
Authors: Kapitany T.; Hesselmann B.; Schindler S.D.; Schindl M.; Barnas C.; Sieghart W.; Kasper S.

Comparative efficacy of moclobemide and imipramine on anxiety features in major depression- a meta-analysis of double blind comparative studies against placebo
pp. S4/80-S4/81(1)
Authors: Delini-Stula A.; Cameron A.; Angst J.

The presynaptic release apparatus: A main site in the mechanism of action of psychotropic drugs
pp. S4/81-S4/81(1)
Authors: Popoli M.; Vocaturo C.; Buffa L.; Venegoni A.; Perez J.; Racagni G.

Pharmacology of the presynaptic terminal: Modifications induced by antidepressant treatment in the phosphorylation of synaptotagmin and its functional properties
pp. S4/81-S4/82(1)
Authors: Popoli M.; Venegoni A.; Buffa L.; Racagni G.

Clinical differences in response to mianserin and fluvoxamine in depressive patients
pp. S4/82-S4/82(1)
Authors: Lavergne F.; Berlin I.

Stimulus properties of mirtazapine resemble those of a 5-HT_1A receptor agonist
pp. S4/82-S4/82(1)
Authors: Berendsen H.H.G.; Broekkamp C.L.E.

Responsiveness of rabbit detrusor, urethra, and trigone strips to imipramine and trazodone
pp. S4/82-S4/83(1)
Authors: Tita B.; Bolle P.; Baldazzi C.; Casini M.L.; Faccendini P.; Faticanti P.; Tucci P.

Responsiveness of rabbit prostate strips to imipramine and trazodone
pp. S4/83-S4/83(1)
Authors: Tita B.; Bolle P.; Baldazzi C.; Casini M.L.; Faccendini P.; Faticanti P.; Tucci P.

Increased D2/D3 dopamine receptor binding associated with pharmacotherapy response before and after treatment of major depression measured by single photon emission computed tomography (SPECT)
pp. S4/83-S4/84(1)
Authors: Klimke A.; Larisch R.; Loffler S.; Vosberg H.; Muller-Gartner H.W.; Gaebel W.

Association study of bipolar disorder and a serotonin receptor polymorphism
pp. S4/84-S4/84(1)
Authors: Mahieu B.; Souery D.; Lipp O.; Demaertelaere V.; Van Broeckhoven C.; Mendlewicz J.

Thyroid function and seizure time during ECT
pp. S4/84-S4/84(1)
Authors: Papakostas Y.; Markianos M.; Pehlivanidis A.; Papadimitriou G.N.; Zervas I.M.; Daras M.; Theodoropoulou M.; Stefanis C.N.

The treatment of dysthymic patients: Fluvoxamine versus amitriptyline
pp. S4/85-S4/85(1)
Authors: Amore M.; Ricci M.; Zazzeri N.

A drug discrimination rocedure in the pigeon confirms the in vitro agonistic action of flesinoxan on the 5-HT_1A receptor
pp. S4/85-S4/85(1)
Authors: Herremans A.H.J.; van der Heyden J.A.M.; Ronken E.; Olivier B.

Antidepressant profile of the 5-HT_1A agonist Flesinoxan in various forced-swim test paradigms
pp. S4/85-S4/86(1)
Authors: van der Heyden J.A.M.; Mos J.; Olivier B.

Plasma arginine vasopressin and motor activity in patients with major depression and in healthy controls
pp. S4/86-S4/86(1)
Authors: van Londen L.; Kerkhof G.A.; van den Berg F.; Goekoop J.G.; Zwinderman A.H.; Frankhuijzen-Sierevogel J.C.; Wiegant V.M.; de Wied D.

Prolyl-leucyl-glycinamide, thyrotropin releasing hormone and -endorphin-(10-16), like antidepressants, inhibit the effects of melatonin on rat behaviour
pp. S4/86-S4/87(1)
Authors: Wolterink G.; Hatta K.; Van Ree J.M.

Potentiation of antidepressants with lithium or carbamazepine
pp. S4/87-S4/87(1)
Authors: Suwalska A.; Rybakowski J.

Mianserin therapy of depressive patients with coexisting cardiovascular diseases
pp. S4/87-S4/87(1)
Authors: Rajewska J.; Rajewski A.

The NMDA receptor and the olfactory bulbectomised rat model of depression
pp. S4/87-S4/88(1)
Authors: Redmond A.M.; Kelly J.P.; Leonard B.E.

The antidepressant effect and tolerability of moclobemide-elderly versus younger patients
pp. S4/88-S4/88(1)
Authors: Stankovic Z.; Zivkovic D.; Bugarski D.; Damjanovic A.

Pindolol augments the antidepressant efficacy of fluoxetine. Results of a double-blind, controlled trial
pp. S4/88-S4/89(1)
Authors: Perez V.; Gilaberte I.; Faries D.; Alvarez E.; Artigas F.

Clinical and experimental sleep study of acute and long-term effects of mood stabilizes
pp. S4/89-S4/89(1)
Authors: Mosolov S.N.; Nerobkova L.N.; Voronina T.A.; Macher J.P.

Antidepressants combined with acupuncture in therapy of endogenous depressions
pp. S4/89-S4/90(1)
Author: Gorobets L.N.

Forskolin effects on behavior in rats and in depressed and schizophrenic patients
pp. S4/90-S4/90(1)
Authors: Bersudsky Y.; Patishi Y.; Shifrina M.; Kotler M.

Clinico-pharmacokinetic prognosis of prophylactic efficacy of carbamazepine, oxcarbazepine and sodium valproate in affective and schizoaffective disorders
pp. S4/90-S4/90(1)
Authors: Kouzavkova M.; Mosolov S.; Kostiukova E.; Singin A.

Use of dopaminergic agonist in treatment of chronic depressive patients resistant to tricyclic antidepressants
pp. S4/90-S4/91(1)
Authors: Tsucarzi E.; Mosolov S.; Missionznik E.; Sharov A.; Uzbekov M.

Quantitative video-analysis of gait in depressed inpatients
pp. S4/91-S4/91(1)
Authors: Hergueta T.; Delgado F.; Lecrubier Y.

Vitamin E inhibits cellular accumulation of desipramine and prevents antidepressant induced -adrenoceptor down-regulation in vitro and in vivo
pp. S4/91-S4/91(1)
Authors: Kientsch U.; Honegger U.E.

Abnormalities of hypothalamus-pituitary-adrenal axis function and natural killer cell activity in Alzheimer's disease
pp. S4/91+S4/94-S4/91+(1
Authors: Griot G.; Prolo P.; Masera R.G.; Lazzero A.; Mantovan M.; Staurenghi A.; Sartori M.L.; Tarenzi L.; Ravizza L.; Angeli A.

Corticotropin-releasing hormone (CRH) neurons in the hypothalamic paraventricular nucleus of depressed and non-depressed parkinsonian patients with and without dementia
pp. S4/94-S4/94(1)
Authors: Hoogendijk W.J.G.; Purba J.S.; Hofman M.A.; de Vos R.A.I.; Steur E.N.H.J.; Swaab D.F.

Peduncular hallucinosis: SSRI efficacy brings new arguments for an old theory
pp. S4/94-S4/95(1)
Authors: Gilles C.; Wuilmart P.; Lasseaux L.; Tecco J.M.; Lorimier P.

Free radical formation level in rabbit brain after experimental craniocerebral trauma
pp. S4/95-S4/95(1)
Authors: Demchuk M.L.; Promyslov M.S.; Poryadina L.V.

Nimotop influence on free radical processes in the CSF of patients with subarachnoid haemorrhages
pp. S4/95-S4/95(1)
Authors: Arefyeva I.A.; Demchuk M.L.; Dausheva A.A.; Belousova O.B.; Myakota A.E.

Changes in composition of phospholipids and fatty acids in rat brain during aging
pp. S4/95-S4/96(1)
Authors: Ripova D.; Nemcova V.

Calcium channel blockers prevent memory impairment induced by the beta-blockers acebutolol and metoprolol
pp. S4/96-S4/96(1)
Authors: Lazarova-Bakarova M.; Genkova-Papasova M.; Petkova B.; Bojanova E.; Staneva-Stoycheva D.

Benzodiazepine binding in T-lymphocytes from parkinsonian patients
pp. S4/96-S4/97(1)
Authors: Bongioanni P.; Castagna M.; Gemignani F.; Mondino C.

Thrombocyte monoamine oxidase molecular activity in demented and parkinsonian patients
pp. S4/97-S4/97(1)
Authors: Bongioanni P.; Mondino C.; Borgna M.; Gemignani F.

Thrombocyte phenolsulphotransferase and monoamine oxidase activity, and benzodiazepine binding in patients with dementia of Alzheimer type
pp. S4/97-S4/98(1)
Authors: Bongioanni P.; Gemignani F.; Castagna M.; Boccardi B.; Ronato M.

Long-acting neuroleptics treatment of patients in residential rehabilitation programs
pp. S4/98-S4/98(1)
Authors: Codazzi L.; Giannelli A.; Rabboni M.

Maintenance of calcium-mediated metabolic control as a therapeutic principle in energy-compromised neurological disorders
pp. S4/98-S4/98(1)
Author: Heininger K.

Neuro-immuno-pharmacological effects of flobufen in model experiments with aging rats
pp. S4/98-S4/99(1)
Authors: Benesova O.; Tejkalova H.; Panajotovova V.; Kristofikova Z.; Husek P.; Klaschka J.

Risperidone is well tolerated by organic brain syndromes
pp. S4/99-S4/99(1)
Authors: Pourcher E.; Bouchard R.H.; Chasse F.

H₁-blockers induce deficit in active and passive avoidance performance in rats
pp. S4/99-S4/99(1)
Authors: Georgieva V.; Todorov S.; Lazarova-Bakarova M.

Investigation of the selectivity of vesamicol analogues as markers for cholinergic neurons: Potential ligands for single photon emission computerized tomography (SPECT) in Alzheimer's disease
pp. S4/99-S4/100(1)
Authors: Custers F.G.J.; Herscheid J.D.M.; Stoof J.C.; Leysen J.E.

Novel substituted acyl-prolyl dipeptide, GVS-111, diminishes cognitive impairment on the model of ischemic stroke in rats
pp. S4/100-S4/100(1)
Authors: Romanova G.A.; Ostrovskaya R.U.; Gudasheva T.A.

Reduced Gs protein function and Gs levels in leukocytes of patients with Parkinson's disease
pp. S4/100-S4/100(1)
Authors: Barki-Harrington L.; Avissar S.; Herishanu Y.; Schreiber G.

Amiridin efficacy in Alzheimer's disease and multi-infarct dementia: The resemblance and the distinction
pp. S4/100-S4/101(1)
Authors: Bukatina E.E.; Grygorieva I.V.; Smirnov O.R.

Phencyclidine (PCP) alters excitability in CA1 hippocampal neurons by inhibiting local circuit inhibition and increasing transmembraneous calcium influx
pp. S4/101-S4/101(1)
Authors: Grunze H.; Hearn E.; Rainnie D.; Berger M.; McCarley R.; Greene R.

Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects
pp. S4/101-S4/101(1)
Authors: van Berckel B.N.M.; Lipsch C.; Timp S.; Gispen-de Wied C.; Wynne H.; van Ree J.M.; Kahn R.S.

Case-control and neuro-imaging study in persons with schizophrenia after prenatal exposure to the Dutch Famine in 1945
pp. S4/102-S4/102(1)
Authors: Kalkman J.S.; Hoek H.W.; Susser E.S.; Kahn R.S.

Optimized analysis of the D2 dopamine receptor occupancy by image fusion of corresponding I-123 IBZM-SPECT and MR-DATA
pp. S4/102-S4/102(1)
Authors: Mager T.; Dresel S.; Tatsch K.; Pfluger T.; Moller H.-J.; Hahn K.

D2 dopamine receptor occupancy (IBZM-SPECT) and extrapyramidal symptoms under treatment with risperidone
pp. S4/102-S4/102(1)
Authors: Mager T.; Dahne I.; Dresel S.; Fajonk F.; Tatsch K.; Moller H.-J.

Event-related potentials and selective auditory and visual attention in autism
pp. S4/102-S4/103(1)
Authors: Hoeksma M.R.; Kemner C.; Verbaten M.N.; Engeland H.V.

Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers
pp. S4/103-S4/103(1)
Authors: Perault M.C.; Bergougnan L.; Paillat A.; Gomeni C.; Zieleniuk I.; Vandel B.

Dopaminergic and nicotinic interactions in the human striatum in Dementia with Lewy bodies, chronic schizophrenia and Parkinson's disease
pp. S4/103-S4/104(1)
Authors: Piggott M.A.; Court J.A.; Perry E.K.; Lloyd S.; Thomas N.J.; Smith Z.M.; Johnson M.; Perry R.H.; McKeith I.G.

Risperidone treatment of schizophrenia: Clinical experience
pp. S4/104-S4/104(1)
Authors: Spisla C.; Baciu D.; Bunter M.; Billeter U.

Treating poor prognosis schizophrenia
pp. S4/104-S4/104(1)
Authors: Moreno A.C.; Pinero M.V.; Calo J.J.P.; Gracia A.C.

Effects of clozapine on neutrophils' chemotaxis
pp. S4/104-S4/105(1)
Authors: Guaraldi G.P.; Fagiolini A.; Salati R.; Donati D.; Donati C.; Venuta M.

Combined use of carbamazepine and valproic acid in negative symptom schizophrenia
pp. S4/105-S4/105(1)
Authors: Lee M.-S.; Choi B.-H.; Kim S.-H.

Comorbid mood disturbance in schizophrenia
pp. S4/105-S4/105(1)
Authors: Tollefson G.D.; Y. L.

Amisulpride in the treatment of productive schizophrenia
pp. S4/105-S4/106(1)
Authors: Rein W.; Turjanski S.; Fleurot O.

Amisulpride in the treatment of deficit schizophrenia
pp. S4/106-S4/106(1)
Authors: Rein W.; Fleurot O.; Turjanski S.

Olanzapine in the treatment of schizoaffective disorder
pp. S4/106-S4/106(1)
Authors: Y. L.; Sanger T.; Beasley C.; Tran P.; Tollefson G.

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute treatment
pp. S4/106-S4/106(1)
Authors: Dellva M.A.; Satterlee W.; Tran P.V.; Beasley C.; Greaney M.; Tollefson G.D.

Clozapine in refractory schizophrenic disorders: A longitudinal study of efficiency, tolerability and clinical improvement during a period up to four years
pp. S4/107-S4/107(1)
Authors: Maitre L.; Poisson N.; Gekiere F.; Dessalles M.C.; Bouchez J.; Guerin V.

An aminopyrimidine with potent affinity for both dopamine and serotonin receptors
pp. S4/107-S4/107(1)
Authors: Wustrow D.; Akunne H.; Belliotti T.; Davis M.D.; Heffner T.; Kesten S.; Meltzer L.; Pugsley T.; Wise L.

Functional hypofrontality revealed by EEG coherence analysis of 16 antipsychotic-free schizophrenic patients performing cognitive activation paradigms
pp. S4/107-S4/108(1)
Authors: Tauscher J.; Rappelsberger P.; Neumeister A.; Fischer P.; Kasper S.

Chronic immunological process in schizophrenia
pp. S4/108-S4/108(1)
Authors: Sluzewska A.; Rybakowski J.K.; Sobieska M.; Linka M.

Hydroxylation polymorphism of debrisoquin hydroxylase (CYP2D6) in a population of psychotic patients in Norway and Denmark
pp. S4/108-S4/108(1)
Authors: Dahl A.A.; Asserson S.; Fogh M.; Kristensen F.; Nyquist O.G.; Toeth S.; Maehlum E.

Positron emission tomography in schizophrenic patients treated with sertindole and haloperidol
pp. S4/109-S4/109(1)
Authors: Buchsbaum M.S.; Hazlett E.; Haznedar M.; Mack R.J.; Sebree T.B.

The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients
pp. S4/109-S4/109(1)
Authors: Baker R.W.; Mack R.J.; Morris D.D.; Sebree T.B.; Kashkin K.B.

Reduction of hospital days in sertindole treated patients-one year findings
pp. S4/109-S4/110(1)
Authors: Braus A.; Nabulsi A.; Mack R.; Sebree T.; Holgate K.

The patient under neuroleptic treatment: Study of prescription practice in psychiatry in France
pp. S4/110-S4/110(1)
Authors: Lachaux B.; Gaussares C.; Terra J.L.

Study of maternal influenza during pregnancy as a risk factor in schizophrenia
pp. S4/110-S4/111(1)
Authors: Rouillon F.; Azorin J.M.; Cohen J.M.; Dassa D.; Payan C.; Strub N.

Epidemiological study on extrapyramidal side effects with neuroleptics
pp. S4/111-S4/111(1)
Authors: Berardi D.; Giannelli A.; Biscione R.; Dell'Atti M.; Ferrari G.

The safety profile of amisulpride, an ''atypical'' antipsychotic
pp. S4/111-S4/111(1)
Authors: Favennec C.; Rein W.; Turjanski S.

No evidence of association between dopamine D₃ receptor gene and bipolar disorder in a sardinian sample
pp. S4/112-S4/112(1)
Authors: Severino G.; Palmas M.A.; Ruiu S.; Del Zompo M.; Piccardi P.

The preclinical profile of an original pyridobenzoxazepine, JL 13
pp. S4/112-S4/112(1)
Authors: Liegeois J.-F.; Bruhwyler J.; Goudie A.J.; Taylor A.; Damas J.; Delarge J.; Geczy J.

Rat tardive dyskinesia is mediated by PI linked D-1 dopamine receptor subtype
pp. S4/112-S4/113(1)
Authors: Rosengarten H.; Friedhoff A.J.

Immunosuppressive effect of neuroleptic drugs--Is it integrated in their antipsychotic action?
pp. S4/113-S4/113(1)
Authors: Leykin I.; Mayer R.; Deckmann M.; Shinitzky M.

A polymorphic region in the human tyrosine hydroxylase gene is associated with disturbances of the catecholaminergic system in schizophrenia
pp. S4/113-S4/113(1)
Authors: Thibaut F.; Ribeyre J.-M.; Dollfus S.; Dourmap N.; Meloni R.; Laurent C.; Campion D.; Mallet J.; Petit M.

The effects of benzodiazepines - hypnotics on performance and recent memory during the therapy of insomnia in schizophrenic patients
pp. S4/113-S4/114(1)
Authors: Jasovic-Gasic M.; Nikolic-Balkoski G.; Kuzmanovic V.; Tasic A.

Pramipexole as an adjunct to haloperidol in schizophrenia
pp. S4/114-S4/114(1)
Authors: Barnas C.; Heiden A.; Volz H.P.; Laakmann G.; Zeit H.; Pfolz H.; Kasper S.

Antibodies to human heat shock protein in patients with schizophrenia and major depression
pp. S4/114-S4/114(1)
Authors: Sirota P.; Mazeh D.; Novogrotsky A.

The effect of neuroleptic drugs on olfactory sensitivity in schizophrenia
pp. S4/114-S4/114(1)
Authors: Sirota P.; Ben-David I.; Luca-Haimovici K.; Zohar J.; Gross-Isseroff R.

Regulation of AP-1 transcription complex in the CNS by antipsychotics
pp. S4/114-S4/114(1)
Authors: Rogue P.; Malviya A.N.; Vincendon G.

Olanzapine versus haloperidol: Results of the international trial
pp. S4/115-S4/115(1)
Authors: Tran P.V.; Dellva M.A.; Tamura R.; Krueger J.; Beasley C.M.; Tollefson G.D.

Acute phase efficacy and safety of olanzapine: A review
pp. S4/115-S4/115(1)
Authors: Kuntz A.; Tran P.; Dellva M.A.; Sanger T.; Beasley C.; Tollefson G.D.

Long-term continuation therapy with the novel antipsychotic olanzapine: A review of the clinical experience
pp. S4/115-S4/115(1)
Authors: Tran P.V.; Dellva M.A.; Rampey V.; Tollefson G.D.; Beasley C.M.

Social functioning and psychopathology of people in long-term psychiatric day care. Influence of new and classical neuroleptics on patient's outcome
pp. S4/116-S4/116(1)
Authors: Nicolaou S.; Fazzari G.; Gozio C.; Este R.; Giuliattini M.

Attentional abnormalities in an animal model for developmental disorders of the entorhinal cortex
pp. S4/116-S4/117(1)
Authors: Talamini L.M.; Korf J.

Clozapine treatment and psychosocial rehabilitation on schizophrenia longitudinal study on positive and negative symptoms in neuroleptic non responder patients
pp. S4/117-S4/117(1)
Authors: Marchetti S.; Palagini L.; Pietrini P.; Starnini S.; Giuntoli L.; Parrini A.

Effects of clozapine on medial prefrontal cortical cells: A presynaptical hypothesis
pp. S4/117-S4/117(1)
Authors: Gobbi G.; Barbieri A.; Janiri L.; Tempesta E.; De Risio S.

Risperidone in the treatment of psychosis and concomitant buccolinguo-masticatory dyskinesia
pp. S4/117-S4/118(1)
Author: Koponen H.J.

Bizarre delusions and age of onset in schizophrenic patients
pp. S4/118-S4/118(1)
Authors: Dikeos D.G.; Papadimitriou G.N.; Daskalopoulou E.G.; Stefanis C.N.

Depressive symptoms in stable chronic schizophrenia: Prevalence and relationship to psychopathology and medication status
pp. S4/118-S4/118(1)
Authors: Mulholland C.; Baynes D.; Montgomery R.; Lynch G.; MacFlynn G.; Kelly C.; Cooper S.J.; King D.J.

Neuroleptic malignant syndrome and psychosis in two siblings with gangliosidosis type II
pp. S4/119-S4/119(1)
Authors: Manor I.; Hermesh H.; Munitz H.; Weizman A.

Muscle enzymes and white blood count as risk factors for the neuroleptic malignant syndrome
pp. S4/119-S4/119(1)
Authors: Hermesh H.; Manor I.; Gianella M.; Munitz H.; Weizman A.

First episode schizophrenia: Treatment and outcome
pp. S4/119-S4/120(1)
Authors: Amore M.; Katia M.; D'Ambrosio S.; Mesa J.M.

Detection of 5HT₇ receptors using [³H]risperidone: A brain regional distribution
pp. S4/120-S4/120(1)
Authors: Gommeren W.; Janssen P.F.M.; Schotte A.; Leysen J.E.

Prevalence of refractory depression and therapeutic strategies in an italian out-patient mental health department
pp. S4/120-S4/120(1)
Authors: Cittadini A.; Figura A.; Gemignani A.; Guerrini I.; Dani A.; Guazzelli M.

Disturbed stress response in Multiple Complex Developmental Disorder and schizophrenia: Salivary cortisol response to a psychological stressor as a measure
pp. S4/121-S4/121(1)
Authors: Jansen L.M.C.; Gademan P.J.; De Jonge R.C.J.; Van Engeland H.; Kahn R.S.; Gispen-de Wied C.C.

Treatment costs of schizophrenic patients
pp. S4/121-S4/121(1)
Authors: Thys E.; De Hert M.; Peuskens J.; Boydens J.; Kesteloot K.; Gilis P.; Verhaegen L.

Stimulation of serotonin (5-HT)_1A autoreceptors enhances dopamine (DA) and noradrenaline (NAD) release in rat frontal cortex: influence of S 15535, WAY 100,635 and 8-OH-DPAT
pp. S4/121-S4/122(1)
Authors: Lejeune F.; Gobert A.; Rivet J.-M.; Newman-Tancredi A.; Audinot V.; Millan M.J.

A comparison of the incidence of long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol
pp. S4/122-S4/122(1)
Authors: Street J.S.; Tamura R.N.; Sanger T.M.; Tollefson G.D.

A comparison of extrapyramidal syndromes between olanzapine and placebo in schizophrenia
pp. S4/122-S4/122(1)
Authors: Street J.S.; Dellva M.; Tamura R.N.; Sanger T.M.; Tollefson G.D.

A comparative in vitro and in vivo characterization of the novel dopamine D₃ receptor antagonists, (+)S 14297, nafadotride, GR 103,691 and U 99,194
pp. S4/122-S4/123(1)
Authors: Audinot V.; Gluck L.; Newman-Tancredi A.; Bervoets K.; Deposte I.; Brocco M.; Millan M.J.

Response to risperidone in schizophrenic in-patients refractory to antipsychotics
pp. S4/123-S4/123(1)
Authors: Busse D.; Cano R.; Gimenez-Salinas J.; Sarro S.; Tiffon M.L.

Switching from a conventional antipsychotic (haloperidol) to an atypical antipsychotic ('Seroquel' - ICI 204,636)
pp. S4/123-S4/123(1)
Authors: Hellewell J.S.E.; Hurst B.C.; Link C.G.G.

'SEROQUEL' (ICI 204,636)- Efficacy in treating the negative symptoms of schizophrenia
pp. S4/124-S4/124(1)
Authors: Hurst B.C.; Link C.G.G.

Two long-term neuroleptic resistant patients treated by 'SEROQUEL' (ICI 204,636) an atypical neuroleptic
pp. S4/124-S4/124(1)
Authors: Avnon M.; Goldin V.; Neissburg Y.

The atypical profile of 'Seroquel' (ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients
pp. S4/124-S4/125(1)
Authors: W. W.H.; Arvanitis L.A.

Reduction of the positive symptoms of schizophrenia by 'Seroquel' (ICI 204,636): Results from phase II and III clinical trials
pp. S4/125-S4/125(1)
Authors: Hong W.W.; Arvanitis L.A.

The atypical profile of 'Seroquel' (ICI 204,636) is supported by its lack of induction of extrapyramidal symptoms
pp. S4/125-S4/125(1)
Authors: Hong W.W.; Arvanitis L.A.

The safety of 'Seroquel' (ICI 204,636) in the treatment of elderly subjects with psychotic disorders
pp. S4/126-S4/126(1)
Authors: Hong W.W.; Aravanitis L.A.; Thyrum P.T.; Wong Y.W.J.

Methodological issues in the outcomes assessment of a new, atypical antipsychotic
pp. S4/126-S4/126(1)
Authors: Drummond M.F.; Knapp M.R.J.; Burns T.P.; Miller K.D.; Ruiz R.

The effects of neonatal bilateral ventral hippocampal lesions on behavior in the rat
pp. S4/127-S4/127(1)
Authors: Daenen E.W.P.M.; Dautzenberg G.M.F.C.; Wolterink G.; Van Ree J.M.

Enzymes of the antioxidant system in type II schizophrenia
pp. S4/127-S4/127(1)
Authors: Paunovic V.R.; Miljevic C.D.; Nikolic A.; Saicic Z.; Babinski T.; Spasic M.B.

Enzymes of the antioxidant system in Type I schizophrenia
pp. S4/127-S4/128(1)
Authors: Miljevic C.D.; Nikolic A.; Damjanovic A.; Saicic Z.; Spasic M.B.; Paunovic V.R.

Peculiarifies of psychopharmacotherapy for prolonged depressive-delusional states with resistance phenomena
pp. S4/128-S4/128(1)
Author: Emelyanova I.N.

Effect of long-term maintenance psychotropic therapy on occupational adaptation of schizophrenic patients
pp. S4/128-S4/128(1)
Author: Kiryanova E.M.

Effect of plasmapheresis in the treatment of drug-resistant schizophrenic patients with biochemical and immunological control
pp. S4/128-S4/129(1)
Authors: Malin D.I.; Uzbekov M.G.; Misionzhnic E.Y.; Domashneva I.V.; Neduva S.S.; Mosolov S.N.

Abnormal regional cerebral blood flow in opioid dependent patients
pp. S4/129-S4/129(1)
Authors: Fischer G.; Diamant K.; Pezawas L.; Schindler S.; Podreka I.; Kasper S.

Norharman in multiple drug-addicts and healthy controls
pp. S4/129-S4/129(1)
Authors: Fekkes D.; Timmerman L.; van Gelderen G.J.; Pepplinkhuizen L.

Cortisol and temperature responses to flesinoxan in alcoholism
pp. S4/129-S4/130(1)
Authors: Pitchot W.; Ansseau M.; Hansenne M.; Barbier V.; Moreno A.G.

Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in isolated tissues
pp. S4/130-S4/130(1)
Authors: Capasso A.; Sorrentino L.

Antibodies to serotonin and cathecholamines as neuroimmunumodulators in experimental opiate addiction
pp. S4/130-S4/130(1)
Authors: Basharova L.A.; Evseyev V.A.; Trekova N.A.; Vetrile L.A.

Effects of nitric oxide synthase inhibition on ethanol withdrawal syndrome in rats
pp. S4/130-S4/131(1)
Authors: Uzbay I.T.; Erden B.F.; Sever B.

The involvement of voltage-dependent Ca²⁺ channel in effects of acutely and chronically administered LSD on biogenic amine metabolism in various areas of rat brain
pp. S4/131-S4/131(1)
Authors: Antkiewicz-Michaluk L.; Romanska I.

Chronic mild stress causes a decrease in the preference for low ethanol concentrations in male Wistar rats
pp. S4/131-S4/131(1)
Authors: Smith J.W.; Remy S.M.; Schreiber R.; De Vry J.

A parametric evaluation of the effects of cyanamide on ethanol intake and preference in rats
pp. S4/131-S4/132(1)
Authors: Remy S.M.; de Beun R.; Schreiber R.; De Vry J.

Interferon and interleukin-2 as modulators of alcohol behavioral reactions in C57B1/6 mice
pp. S4/132-S4/132(1)
Authors: Fomina V.G.; Davidova T.V.; Pletsityi K.D.

The effect of ACPC, a partial agonist of glycine receptors, on motivational aspects of morphine dependence
pp. S4/132-S4/132(1)
Author: Papp M.

Is anhedonia a predictive factor for relapse in alcohol dependence?
pp. S4/132-S4/133(1)
Authors: Marra D.; Warot D.; Payan C.; Hispard E.; Dally S.; Puech A.J.

5-HT2 blocker ritancerin attenuates the behavioral expression of precipitated morphine abstinence
pp. S4/133-S4/133(1)
Authors: Kudryashova M.F.; Verbitskaya E.V.

Clozapine treatment of severe tardive dystonia
pp. S4/133-S4/134(1)
Authors: Cavallaro R.; Smeraldi E.

EEG and event related potentials as indicators of central neurophysiological effects of acamprosate
pp. S4/134-S4/134(1)
Authors: Gallinat J.; Hegerl U.; Moller H.-J.

Effects of and opioid agonists on the cholecystokinin-induced activation of opioid system in isolated guinea-pig ileum
pp. S4/134-S4/134(1)
Authors: Romanelli L.; Valeri P.; Amico M.C.; Mattioli F.

Trazodone versus clonidine in rapid detoxification from opiates
pp. S4/134-S4/135(1)
Authors: Conte G.L.; Scetta G.; Moscianese K.; Pozzi G.

Depression and false depression in alcoholism: An application of brain mapping
pp. S4/135-S4/135(1)
Authors: Garrido A.; Cabanyes J.

Neuroendocrine effects of methylenedioxyethylamphetamine (MDE) in healthy volunteers: Preliminary results of an ongoing human experimental study
pp. S4/135-S4/135(1)
Authors: Gouzoulis-Mayfrank E.; Thelen B.; Habermeyer E.; Kock A.; Sass H.

Cloning and characterization of a rat -opioid receptor isoform (rMOR1B)
pp. S4/136-S4/136(1)
Authors: Zimprich A.; Kraus J.; Mayer P.; Hollt V.

Results of cognitive-behavioral therapy supported by piracetam and computerized cognitive skills (re)training in alcoholics
pp. S4/136-S4/136(1)
Authors: Schett P.; Haller R.; Hinterhuber H.

Codependency and personality traits in alcoholics and their partners
pp. S4/136-S4/137(1)
Authors: Janiri L.; Onni M.; Hadjichristos A.; Rago R.; Sarchiapone M.; De Risio S.

Different traits of personality and Cloninger's types of alcoholism
pp. S4/137-S4/137(1)
Authors: Hadjichristos A.; Rago R.; Pozzi G.; Fontana S.; Genualdo A.; Janiri L.

Treatment of inhalation toxicomania with phenothiazine piperazine derivatives (PPD)
pp. S4/137-S4/137(1)
Author: Mikhailov M.A.

Survival analysis of patients with one vs. multiple treatment attempts in a naltrexone program
pp. S4/137-S4/137(1)
Authors: Ochoa E.; Baca-Garcia E.

Increased oxidative stress in alcohol dependent patients as estimated by the in vivo acetylsalicylic acid assay (ASAA)
pp. S4/138-S4/138(1)
Authors: Thome J.; Gerlach M.; Zhang J.; Davids E.; Foley P.; Wodarz N.; Wiesbeck G.A.; Boning J.; Riederer P.

Preliminary findings on the role of fluvoxamine in the treatment of alcoholism
pp. S4/138-S4/139(1)
Author: Vrasti R.

The effect of ethnic belonging of drug addicts on the structure and the treatment period of the abstinent syndrome for some forms of drug addiction
pp. S4/139-S4/139(1)
Author: Krivogornitsina H.A.

The relevance of prolonged aversive stimulation stress model for the research of anxious and depression
pp. S4/139-S4/139(1)
Author: Sukhotina I.A.

Fluvoxamine in the treatment of obsessive-compulsive disorder: A double-blind comparison with clomipramine
pp. S4/139-S4/140(1)
Authors: Mundo E.; Smeraldi E.; Bellodi L.

A comparison of the full 5-HT_1A agonist flesinoxan with other 5-HT_1A agonists: Effects on behaviour and a quantification of (partial) agonism on cells
pp. S4/140-S4/140(1)
Authors: Mos J.; Ronken E.; Cramer W.C.C.; Molewijk E.M.; van der Heyden J.A.M.; Olivier B.

Treatment maintenance time in panic disorder with or without agoraphobia
pp. S4/140-S4/140(1)
Authors: Corominas A.; Vallejo J.

A reappraisal of the role of serotonin versus GABAergic interaction in emotional control
pp. S4/140-S4/141(1)
Authors: Nazar M.; Plaznik A.

Flesinoxan in generalised anxiety disorder: A meta-analysis of two double-blind, placebo-controlled comparisons with alprazolam
pp. S4/141-S4/141(1)
Authors: de Voogd J.M.; van den Berg S.J.

Long-term effects of alprazolam on memory: A 3 12 year follow up of agoraphobic patients
pp. S4/141-S4/141(1)
Authors: Kilic C.; Curran V.C.; Noshirvani H.; Basoglu M.; Marks I.M.

A new method to quantify effects of benzodiazepines on normal daily activities: Ambulatory accelerometry in psychopharmacological research
pp. S4/142-S4/142(1)
Authors: Tulen J.H.M.; Bussmann J.B.J.

Sympatho-adrenomedullary activity during mental stress and orthostatic challenge: Effects of alprazolam and lorazepam
pp. S4/142-S4/142(1)
Authors: Tulen J.H.M.; Boomsma F.; Pepplinkhuizen L.

Fluoxetine treatment of children and adolescents with obsessive-compulsive disorders: A open-label trial
pp. S4/142-S4/143(1)
Authors: Baysal Z.B.; Unal F.

Pharmacotherapy and brief dynamic psychotherapy of panic disorder
pp. S4/143-S4/143(1)
Authors: Dahl A.A.; Wiborg I.M.

Safety profile of flesinoxan; results form a meta-analysis of studies in patients with major depressive disorder or generalised anxiety disorder
pp. S4/143-S4/144(1)
Authors: de Voogd J.M.; Stevens G.

Pharmacological treatment of social phobia: A controlled study with alprozolam and buspirone
pp. S4/144-S4/144(1)
Author: Krylov V.I.

Flesinoxan treatment of Generalized Anxiety Disorder: A fixed dose, placebo-controlled trial
pp. S4/144-S4/144(1)
Authors: Noel F.; Stevens G.; Bradford D.

Correlates and course of irritability and disinhibition during alprazolam treatment of panic disorder
pp. S4/144-S4/144(1)
Authors: Starcevic V..; Kelin K.

Fluvoxamine for children and adolescents with Obsessive Compulsive Disorder: A controlled multicenter trial
pp. S4/144-S4/145(1)
Authors: Riddle M.A.; Claghorn J.; Gaffney G.; Greist J.; Holland D.; Landbloom R.; McConville B.; Piggott T.; Pravetz M.; Walkup J.; Yaryura-Tobias; Houser V.

Discrimination between the 5-HT₁ receptor agonists flesinoxan and eltoprazine
pp. S4/145-S4/145(1)
Authors: Gommans J.; Hijzen T.H.; Maes R.A.; Olivier B.

Anxiolytic effects found in the fear-potentiated startle response paradigm are not due to a non-specific disruption of startle behavior
pp. S4/145-S4/146(1)
Authors: Joordens R.J.E.; Hijzen T.H.; Olivier B.

Repeated flesinoxan administration in rats: Dissociation of hormonal and behavioural effects
pp. S4/146-S4/146(1)
Authors: Groenink L.; van der Gugten J.; Olivier B.

Monoaminergic systems in patients with Obsessive-Compulsive Disorder (OCD) before and after fluoxetine treatment
pp. S4/146-S4/146(1)
Authors: Prolo P.; Albert U.; Maina G.; Ravizza L.; Bogetto F.; Abrigo C.; Gennaro M.C.; Frattini P.; Santagostino G.

Fluoxetine treatment of comorbid premature ejaculation and panic disorder
pp. S4/146-S4/147(1)
Authors: Kindler S.; Dolberg O.T.; Kotler M.

Effect of flesinoxan on the electrocorticogram of the rat
pp. S4/147-S4/147(1)
Authors: Nievelstein H.; Krijzer F.; van der Heijden J.; Olivier B.

Efficacy of the full 5-HT_1A receptor agonist flesinoxan compared with other 5-HT_1A agonists in animal models for anxiety
pp. S4/147-S4/148(1)
Authors: Mos J.; Cramer W.C.M.; van der Heyden J.A.M.; Molewijk H.E.; Olivier B.

Characteristics of patients with a prescription of benzodiazepine
pp. S4/148-S4/148(1)
Authors: Barnas C.; Frohlich S.; Whithworth S.; Miller C.; Fleischhacker W.W.

Combination of two SSRI's in long-term treatment of patients with OCD-four case reports
pp. S4/148-S4/148(1)
Author: Palova E.

Efficacy of different serotonergic drugs in obsessive-compulsive disorder
pp. S4/148-S4/149(1)
Authors: Pfanner C.; Presta S.; Gemignani A.; Milanfranchi A.; Lensi P.; Ravagli S.; Maremmani I.; Marazziti D.

Obsessive Compulsive Disorder with episodic course: Is it a mood disorder related subtype?
pp. S4/149-S4/149(1)
Authors: Gemignani A.; Pfanner C.; Presta S.; Milanfranchi A.; Lensi P.; Ravagli S.; Marazziti D.; Maremmani I.; Perugi G.

Comorbidity between obsessive compulsive disorder and unipolar and bipolar disorders
pp. S4/149-S4/149(1)
Authors: Pfanner C.; Presta S.; Gemignani A.; Milanfranchi A.; Lensi P.; Ravagli S.; Marazziti D.; Maremmani I.; Perugi G.

The effect of the neuroactive steroid -THDOC, on staircase test behavior in mice
pp. S4/150-S4/150(1)
Authors: Weizman R.; Peter Y.; Terkel J.; Gavish M.; Pick C.G.

Pharmaco-psychological effects of S(+) DN-2327 enantiomer and DN-2327 racemate
pp. S4/150-S4/150(1)
Authors: Dietrich B.; Pabst G.

Clinical effects of buspirone in social phobia, a double-blind placebo controlled study
pp. S4/150-S4/150(1)
Authors: van Vliet I.M.; den Boer J.A.; Westenberg H.G.M.; Ho Pian K.L.

EEG abnormalities in anxiety disorders
pp. S4/150-S4/151(1)
Authors: Brzezinski R.; Dabkowski M.; Araszkiewicz A.; Uziallo J.

The effects of meta-chlorophenylpiperazine at cerebral blood flow and behavior in Obsessive Compulsive Disorder (OCD). Is the cerebellum involved in OCD?
pp. S4/151-S4/151(1)
Authors: Pian K.L.H.; Westenberg H.G.M.; den Boer J.A.; de Bruin W.I.; van Rijk P.P.

Characterization of [³H]GR 125,743 as a radioligand at 5-HT_1D receptors in guinea pig brain: A comparison with [³H]5CT
pp. S4/151-S4/151(1)
Authors: Audinot V.; Lochon S.; Millan M.J.

Dopaminergic properties of the 5-HT_1A receptor antagonists WAY-100,635 and (S)-UH-301
pp. S4/151-S4/152(1)
Authors: Ahlenius S.; Henriksson I.; Magnusson O.

Urinary excretion of cortisol, norepinephrine, epinephrine, testosterone, and melatonin in panic disorder
pp. S4/152-S4/152(1)
Authors: Bandelow B.; Sengos G.; Wedekind D.; Huether G.; Pilz J.; Broocks A.; Hajak G.; Ruther E.

Efficacy measurement with the new panic and agoraphobia scale by using a new nonparametric test for repeated measures
pp. S4/152-S4/152(1)
Authors: Bandelow B.; Brunner E.; Broocks A.; Hajak G.; Beinroth D.; Ruther E.

Panic disorder and agoraphobia: What is effective?
pp. S4/152-S4/152(1)
Authors: Bandelow B.; Sievert K.; Rothemeyer M.; Ruther E.

Treatment outcome in poor metabolizers versus extensive metabolizers in a population of psychotic patients in Denmark and Norway
pp. S4/153-S4/153(1)
Authors: Bjarking L.; Lowert A.; Andersen P.J.; Lindberg S.; Bratholm J.; Berglund J.; Norum D.; Hansen T.S.; Bayer L.

The evaluation of fluvoxamine in the treatment of social phobia
pp. S4/153-S4/153(1)
Authors: DeVane C.L.; Ware M.R.; Emmanual N.P.; Brawman-Mintzer O.; Lydiard R.B.

Intracerebroventricular (icv) administration of CCK-antisense oligodeoxynucleotides prevent anxiety-behavior in rats
pp. S4/153-S4/154(1)
Authors: Cohen H.; Kaplan Z.; Kotler M.

Serotonin depletion affects both motor and anti-conflict effects of competitive and noncompetitive NMDA receptor antagonists
pp. S4/154-S4/154(1)
Authors: Jessa M.; Plaznik A.

The development of home-seeking behavior in rat pups
pp. S4/154-S4/155(1)
Authors: Sigling H.O.; Gispen W.-H.; van Engeland H.; Spruijt B.M.

Lamotrigine may limit pathological excitation by modulating calcium- and potassium currents
pp. S4/155-S4/155(1)
Authors: Grunze H.; Wegerer J.V.; Walden J.

A comparison of zolpidem and temazepam in psychophysiological insomaniacs
pp. S4/155-S4/156(1)
Authors: Kerkhof G.A.; van Vianen B.G.; Kamphuisen H.A.C.

Attentional capacity in normal control and ADHD children, a probe ERP study
pp. S4/156-S4/156(1)
Authors: Jonkman L.M.; Kemner C.; Verbaten M.N.; van Engeland H.; Koelega H.S.; Camfferman G.; Buitelaar J.K.

Eye movements of autistic children
pp. S4/156-S4/156(1)
Authors: van der Geest J.N.; Kemner C.; van Engeland H.; Verbaten M.N.

The analgetic activity of the new analog of ACTH (4-10) fragment in patients with migraine attack
pp. S4/156-S4/157(1)
Authors: Dubinin V.A.; Koroleva M.V.; Meyzerov E.E.; Levitskaya N.G.; Nezavibatko V.N.; Kamensky A.A.

Effects of repeated administration of desipramine and fluoxetine on vasopressin-induced grooming in rats
pp. S4/157-S4/157(1)
Authors: Lightowler S.; Blackburn T.P.; Kennett G.A.

Role of noradrenergic, dopaminergic, serotonergic and opioidergic systems on the effect of neonatal handling in learned helplessness
pp. S4/157-S4/158(1)
Authors: Tejedor-Real P.; Costela C.; Mico J.A.; Gibert-Rahola J.

The effects of delta sleep inducing peptide on burying behavior in rats with active and passive behavioral strategies
pp. S4/158-S4/158(1)
Author: Strekalova T.V.

Biochemical and neuroendocrinergic indicators of aggressive behavior: A controlled study
pp. S4/158-S4/158(1)
Authors: Cetin M.; Cilden S.; Burkovik Y.

Psychiatric and psychosocial assessment of deliberate self-mutulation in: A controlled study
pp. S4/158-S4/159(1)
Authors: Cetin M.; Ozcubukcuoglu A.; Tarhan N.; Senyuz L.; Burkovik Y.

Expression of IL-6 receptor mRNA in the hypothalamus of restrained rat
pp. S4/159-S4/159(1)
Authors: Komori T.; Fujiwara R.; Shizuya K.; Nomura J.

CNS depressant effects of olfactory stimulation in rats
pp. S4/159-S4/159(1)
Authors: Komori T.; Tanida M.; Kikuchi A.; Shoji K.; Nakamura S.; Nomura J.

Cholecystokinin peptides in cerebrospinal fluid: Findings in healthy male volunteers
pp. S4/160-S4/160(1)
Authors: Gunnarsson T.; Eklundh T.; Eriksson M.; Sjoberg S.; Nordin C.

The role of nitric oxide in chemically and electrically induced convulsions in mice
pp. S4/160-S4/160(1)
Authors: Przegalinski E.; Baran L.; Siwanowicz J.

ERP waves of ADHD- and normal control children in a continuous performance test
pp. S4/160-S4/160(1)
Authors: Overtoom C.C.E.; Kemner C.; Koelega H.S.; Buitelaar J.K.; van der Gaag R.J.; van Engeland H.; Verbaten M.N.

Pharmacokinetic-pharmacodynamic modelling of the interaction between phenytoin and sodium valproate
pp. S4/160-S4/161(1)
Authors: Della Paschoa O.E.; Voskuyl R.A.; Danhof M.

Assessment of the pharmacodynamic interaction between phenytoin and sodium valproate by ictal behaviour analysis
pp. S4/161-S4/161(1)
Authors: Della Paschoa O.E.; Hamstra R.; Voskuyl R.A.; Kruk M.R.; Danhof M.

New therapeutic strategy for migraine treatment: Desensitization with a dopamine agonist
pp. S4/161-S4/161(1)
Authors: Lai M.; Cherchi A.; Loi V.; Del Zompo M.

Use of psychotropic medication before and after psychotherapeutic inpatient treatment
pp. S4/161-S4/162(1)
Authors: Laux G.; Mey U.

Effects of sex and aging on ³H-paroxetine binding to human platelets
pp. S4/162-S4/162(1)
Authors: Marazziti D.; Rossi A.; Palego L.; Giannaccini G.; Lucacchini A.; Cassano G.B.

Histamine mediates long-term potentiation of excitability in rat hippocampus
pp. S4/162-S4/163(1)
Authors: Selbach O.; Haas H.L.

Acute tyrosine depletion reduces catecholamine synthesis in the rat brain
pp. S4/163-S4/163(1)
Authors: McTavish S.F.B.; Cowen P.J.; Sharp T.

Risperidone in the treatment of Gilles de la Tourette Syndrome
pp. S4/163-S4/163(1)
Authors: Stamenkovic M.; Schindler S.; Aschauer H.N.; Kasper S.

Morphine counteracts the effects of juvenile isolation on later social behaviour
pp. S4/163-S4/164(1)
Authors: van den Berg C.L.; Van Ree J.M.; Spruijt B.M.

Salivary cortisol response to psychological stress in healthy adults and children: Comparison of two different stimuli
pp. S4/164-S4/164(1)
Authors: Jansen L.M.C.; Gademan P.J.; de Jonge R.C.J.; Gispen-de Wied C.C.

Ferment status of lymphocytes in children born by parents with psychic diseases
pp. S4/164-S4/165(1)
Authors: Ternovsky L.N.; Ternovskaya V.A.; Nartsissov R.P.

The opinion about mental illness, with respect to general psychopathology and personality characteristics, in a sample of subjects of a small greek island
pp. S4/165-S4/165(1)
Authors: Trikkas G.; Zafirakopoulou K.

GABA-A receptor antagonists: Sex differences in pharmacokinetics and/or pharmacodynamics?
pp. S4/165-S4/165(1)
Authors: Pericic D.; Bujas M.

Effects of vasopressin metabolites on social recognition in the rat
pp. S4/165-S4/166(1)
Authors: Reijmers L.G.J.E.; Burbach J.P.H.; Spruijt B.M.; van Ree J.M.

The effect of chronic naltrexone treatment on hyperactive behaviour in children with autism
pp. S4/166-S4/166(1)
Authors: Willemsen-Swinkels S.H.N.; Buitelaar J.K.; van Engeland H.

Hypoxia and hyperventilation as models for cognitive deficiencies
pp. S4/166-S4/166(1)
Authors: Hogervorst E.; Riedel W.; Van Boxtel M.; Jolles J.

Effectiveness of pemoline among hyperkinetic children who fail to respond to methylphenidate
pp. S4/166-S4/166(1)
Authors: Winsberg B.G.; Klee S.; Pollack J.

Serotoninergic activity in eating disorders subtypes
pp. S4/167-S4/167(1)
Authors: Ramacciotti C.E.; Marazziti D.; Guidi L.; Bondi E.; Bertozzi G.; Cassano G.B.

Comparison of brain activity patterns during finger opposition with and without tactile stimulation using a BOLD-fMRI method
pp. S4/167-S4/167(1)
Authors: Jansma J.M.; Ramsey N.F.; Meinders L.J.M.; Mali W.P.T.M.; Kahn R.S.

Therapeutical approaches to sexual disadaptation
pp. S4/167-S4/167(1)
Authors: Kibrik N.D.; Reshetnyak J.A.

Utilization of laser therapy in the complex treatment of Tourette's syndrome in children
pp. S4/168-S4/168(1)
Authors: Janumova G.M.; Ivanov L.B.; Zykov V.P.; Alekseeva N.V.; Dakhayeva L.N.